BLCO241220C2500
- 0.00
- 0.000.00%
Bausch + Lomb Corp. Newsroom
Top Gap Ups and Downs on Monday: TSLA, NET, STLA and More
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Downgrades Bausch & Lomb to Equal-Weight, Announces $19 Price Target
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue Eye Care Recycling Programs
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $26
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $23 to $26
Express News | Bausch + Lomb : H.c. Wainwright Raises Target Price to $23 From $22
Bausch & Lomb Analyst Ratings
Bausch + Lomb Corp. | 10-Q: Q3 2024 Earnings Report
Bausch + Lomb Swings to Quarterly Profit, Lifts Full-Year Revenue Target Range
Bausch + Lomb Corp. | 8-K: Bausch + Lomb Announces Third-Quarter 2024 Results
Bausch + Lomb Raises FY24 Revenue Guidance To $4.725B-$4.825B (Prior $4.7B-$4.8B)
Bausch + Lomb Adj. EPS Excluding Acquired IPR&D $0.17
Express News | Bausch & Lomb Q3 Sales $1.196B Beat $1.180B Estimate
Bausch + Lomb Announces Third-Quarter 2024 Results
Press Release: Bausch + Lomb Announces Third-Quarter 2024 Results
Earnings Preview: BLCO to Report Financial Results Pre-market on October 30
Bausch + Lomb Q3 Report Likely to Focus on Potential Sale, Dry Eye Disease Drugs, RBC Says
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $23